In two large-scale case-control studies reported by Dorling et al. and Hu et al., GPVs in BRCA1 were detected in 1.05% and 0.85% of patients with BC and 0.11% and 0.11% of the controls, respectively, whereas GPVs in BRCA2 were detected in 1.54% and 1.29% of patients with BC and 0.26% and 0.24% of the controls, respectively [12,13] (Table 1). This evidence concerns the gene BRCA2 and breast cancer.